First Tracks Biotherapeutics is a clinical-stage biotechnology company that develops antibodies designed to modulate key immune pathways for the treatment of autoimmune and inflammatory diseases. The company's pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. First Tracks Biotherapeutics focuses on generating translational and clinical data to clarify mechanism and differentiation, with the goal of advancing its programs toward global registration and facilitating commercialization while retaining rights in key markets.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage ir.firsttracksbio.com
Sector Healthcare IR page firsttracksbio.com
Tags
antibody therapeutics, autoimmune diseases, inflammatory diseases, immunology, clinical-stage, celiac disease, eosinophilic esophagitis, rheumatoid arthritis, ANB033, rosnilimab, ANB101
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026 Q1 2026
Assets 170.456M 183.14M 290.576M
Net profit -31.356M -33.374M -50.484M
Free cash flow -17.051M -31.943M -32.578M

Figure Q3 2026 Q2 2026 Q1 2026
Share price 35.44 20.12 —
P/FCF -18.66 -5.57 —

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 14.1M
Cash and deposits (USD) 123M 238M
Right-of-use assets (USD) — 12.5M
Reported May 14, 2026 May 14, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease (CeD)

•Completed enrollment for Cohort 2 (mucosal healing) of Phase 1b ANB033 trial in CeD; top-line data anticipated in Q1 2027

•Anticipate initiating late-stage clinical trial for ANB033 in CeD in 2027

•Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis; top-line data anticipated in Q3 2027

•Anticipate initiating Phase 2 development of ANB033 in vitiligo and one additional indication in H1 2027

•Completed private placement with $200 million in gross proceeds; pro forma cash of $343 million

SAN DIEGO, CA — Nov. 3, 2026 — First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the third quarter ended Sept. 30, 2026, and provided a business update.

On October 19, 2026 (the “Closing Date”), First Tracks Biotherapeutics, Inc. (the “Company”) closed its previously announced private placement (the “Private Placement”) of an aggregate 6,106,870 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share. At the closing of the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the investors in the Private Placement (the “Investors”). Pursuant to the Registration Rights Agreement, the Company is required to file or confidentially submit a registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale by the Investors of the Shares as promptly as reasonably practicable, and in any event no later than 30 days following the Closing Date.

The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the Registration Rights Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

October 15, 2026

PDF Version

SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share. First Tracks Biotherapeutics anticipates approximately $200 million in gross proceeds to the company before deducting placement agent fees and other expenses. Closing of the private placement is expected to occur on October 19, 2026, subject to the satisfaction of customary closing conditions.

The private placement included participation from new and existing investors including Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital, a life sciences-focused institutional investor and multiple leading mutual funds.

First Tracks Biotherapeutics intends to use the proceeds from the private placement for general corporate purposes, including for clinical development of ANB033, a CD122 antagonist.

Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities are acting as placement agents for the private placement.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities will not and have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States absent registration or an applicable exemption from registration requirements. First Tracks Biotherapeutics has agreed to file a registration statement with the SEC registering the resale of the common stock sold in the private placement.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: statements relating to the expected timing of closing of the private placement, the intended use of proceeds and the filing of a registration statement. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contact: Nick Montemarano Vice President, Investor Relations 858.732.0178 [email protected]

Search Investors

Prompts

First Tracks Biotherapeutics, Inc. (ticker TRAX), listed in United States.

Company History

Date Change Detail
Mar 3, 2026 Renamed Biopharma Company, Inc. → First Tracks Biotherapeutics, Inc.

ETFs Holding First Tracks Biotherapeutics, Inc.

ETF Weight in ETF Shares Market value As of
CANC 0.38% 19,205 $ 803.537K Aug 31, 2026
HELX 0.20% 2,775 $ 55.833K Jun 30, 2026
SQLV 0.17% 2,441 $ 49.113K Jun 30, 2026
RESM 0.02% 40 $ 804.80 Jun 30, 2026
ESSC 0.00% 14 $ 616.56 Jul 31, 2026
DFAC 0.00% 108 $ 5,259.60 Nov 12, 2026
NTRL short 0.00% -3,746 $ 0.00 Nov 16, 2026